Sølund C, et al. - Researchers examined the differences in adverse events (AEs) and treatment efficacy in 96 patients with chronic hepatitis C (CHC), genotype (GT) 1 or 3, who were randomized to two different treatment arms (1:1). Due to changes in the national treatment guidelines, the GT3 treatment arm was prematurely terminated; thus, only AE data on the GT1 participants are described. AEs occurred in 70 (97%) patients with GT1. Anemia, fatigue, and headache were the most common AEs. No difference was observed in AEs possibly related to the direct-acting antiviral (DAA) regimen in patients with CHC. However, AEs possibly related to the DAA regimen persisted in a significant number of patients after treatment. This finding may be of significance for physicians in relation to patient information concerning AEs possibly related to DAA treatment.